Significant changes at Johnson & Johnson were among the most-read medtech news on MassDevice over the past year.

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Our study assessed the impact of using Control-IQ technology, an automated insulin delivery system, on achievement of a Healthcare Effectiveness Data and Information Set (HEDIS) quality measure ...

MiniMed is pitching the breadth of its portfolio as an advantage over more focused rivals such as Dexcom and Insulet.

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to ...

Rarer diabetes patients in Singapore can now receive up to 80% government subsidies for continuous glucose monitoring (CGM) ...

Senseonics earns a buy with Eversense 365 driving growth, Q3 revenue up 90% YoY, gross margin expansion, and Ascensia ...

Real-time continuous glucose monitoring (rt-CGM) reduced large-for-gestational-age (LGA) births in women with gestational diabetes.

Abbott (NYSE:ABT) announced today that it made its Lingo over-the-counter continuous glucose monitor (CGM) available at Walgreens.

Continuous glucose monitoring may have a role in identifying and preventing diabetes among healthy adults, but more studies ...

Discover why DexCom (DXCM) could rebound in 2025. Explore buyback plans, growth potential, and investment insights in the ...